# Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

> **NCT01820026** · PHASE4 · UNKNOWN · sponsor: **University of Roma La Sapienza** · enrollment: 96 (estimated)

## Conditions studied

- Cirrhosis

## Interventions

- **DRUG:** Imipenem
- **DRUG:** Vancomycin
- **DRUG:** azithromycin
- **DRUG:** Cefotaxime
- **DRUG:** Amoxicillin

## Key facts

- **NCT ID:** NCT01820026
- **Lead sponsor:** University of Roma La Sapienza
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820026, "Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01820026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*